+关注
你好兜
暂无个人介绍
IP属地：山东
1
关注
0
粉丝
0
主题
0
勋章
主贴
热门
你好兜
01-29
说说你对这篇新闻的看法...
英矽智能涨近10%再创新高！开年仅一个月公司已达成三笔重磅合作
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4223622861662892","uuid":"4223622861662892","gmtCreate":1760519658440,"gmtModify":1762044044313,"name":"你好兜","pinyin":"nhdnihaodou","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"山东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":527084014653816,"gmtCreate":1769654077044,"gmtModify":1769654145332,"author":{"id":"4223622861662892","authorId":"4223622861662892","name":"你好兜","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4223622861662892","authorIdStr":"4223622861662892"},"themes":[],"title":"","htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/527084014653816","repostId":"1138825501","repostType":2,"repost":{"id":"1138825501","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1769653715,"share":"https://www.laohu8.com/m/news/1138825501?lang=zh_CN&edition=full","pubTime":"2026-01-29 10:28","market":"hk","language":"zh","title":"英矽智能涨近10%再创新高！开年仅一个月公司已达成三笔重磅合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1138825501","media":"老虎资讯综合","summary":"1月29日，$英矽智能$涨近10%，高见66.5港元，再创历史新高，开年仅一个月公司已达成三笔重磅合作。$浙商证券$发布研报称，AI制药核心价值在于大幅提升药物早研效率，以英矽智能Pharma.AI为例，其能够使候选药物从靶点发现到临床前候选药物确认时间从4.5年大幅缩短到12至18个月，早研阶段的投入产出比大幅提升。该行指出，国内多家AI制药平台服务能力全球领先，海外业务拓展持续高速已验证，关注英矽智能等。","content":"<html><head></head><body><p>1月29日，<a href=\"https://laohu8.com/S/03696\">英矽智能</a>涨近10%，高见66.5港元，再创历史新高，开年仅一个月公司已达成三笔重磅合作。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/af049c1303819858eb7acbf649ab03ac\" tg-width=\"560\" tg-height=\"240\"/></p><p>消息面上，开年仅一个月，英矽<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>已达成三笔重磅合作。1月5日，公司与施维雅达成8.88亿美元研发合作，聚焦创新抗肿瘤疗法；1月20日，与深圳衡泰<a href=\"https://laohu8.com/S/000504\">生物</a>就ISM8969项目达成合作，加速推进全球开发，双方各持50%权益，英矽智能主导IND申报及I期临床试验；1月27日，与齐鲁制药达成超9.31亿港元合作，关注代谢疾病领域新颖小分子药物设计与优化。</p><p style=\"text-align: justify;\"><a href=\"https://laohu8.com/S/601878\">浙商证券</a>发布研报称，AI制药核心价值在于大幅提升药物早研效率，以英矽智能Pharma.AI为例，其能够使候选药物从靶点发现到临床前候选药物确认时间从4.5年大幅缩短到12至18个月，早研阶段的投入产出比大幅提升。该行指出，国内多家AI制药平台服务能力全球领先，海外业务拓展持续高速已验证，关注英矽智能等。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>英矽智能涨近10%再创新高！开年仅一个月公司已达成三笔重磅合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n英矽智能涨近10%再创新高！开年仅一个月公司已达成三笔重磅合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2026-01-29 10:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>1月29日，<a href=\"https://laohu8.com/S/03696\">英矽智能</a>涨近10%，高见66.5港元，再创历史新高，开年仅一个月公司已达成三笔重磅合作。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/af049c1303819858eb7acbf649ab03ac\" tg-width=\"560\" tg-height=\"240\"/></p><p>消息面上，开年仅一个月，英矽<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>已达成三笔重磅合作。1月5日，公司与施维雅达成8.88亿美元研发合作，聚焦创新抗肿瘤疗法；1月20日，与深圳衡泰<a href=\"https://laohu8.com/S/000504\">生物</a>就ISM8969项目达成合作，加速推进全球开发，双方各持50%权益，英矽智能主导IND申报及I期临床试验；1月27日，与齐鲁制药达成超9.31亿港元合作，关注代谢疾病领域新颖小分子药物设计与优化。</p><p style=\"text-align: justify;\"><a href=\"https://laohu8.com/S/601878\">浙商证券</a>发布研报称，AI制药核心价值在于大幅提升药物早研效率，以英矽智能Pharma.AI为例，其能够使候选药物从靶点发现到临床前候选药物确认时间从4.5年大幅缩短到12至18个月，早研阶段的投入产出比大幅提升。该行指出，国内多家AI制药平台服务能力全球领先，海外业务拓展持续高速已验证，关注英矽智能等。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","relate_stocks":{"BK1141":"生命科学工具和服务","BK6092":"保健护理机构","03696":"英矽智能","01477":"欧康维视生物-B","BK6511":"医疗保健服务概念","5RE.SI":"智能"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138825501","content_text":"1月29日，英矽智能涨近10%，高见66.5港元，再创历史新高，开年仅一个月公司已达成三笔重磅合作。消息面上，开年仅一个月，英矽智能已达成三笔重磅合作。1月5日，公司与施维雅达成8.88亿美元研发合作，聚焦创新抗肿瘤疗法；1月20日，与深圳衡泰生物就ISM8969项目达成合作，加速推进全球开发，双方各持50%权益，英矽智能主导IND申报及I期临床试验；1月27日，与齐鲁制药达成超9.31亿港元合作，关注代谢疾病领域新颖小分子药物设计与优化。浙商证券发布研报称，AI制药核心价值在于大幅提升药物早研效率，以英矽智能Pharma.AI为例，其能够使候选药物从靶点发现到临床前候选药物确认时间从4.5年大幅缩短到12至18个月，早研阶段的投入产出比大幅提升。该行指出，国内多家AI制药平台服务能力全球领先，海外业务拓展持续高速已验证，关注英矽智能等。","news_type":1,"symbols_score_info":{"03696":1,"5RE.SI":1,"01477":0.47}},"isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":527084014653816,"gmtCreate":1769654077044,"gmtModify":1769654145332,"author":{"id":"4223622861662892","authorId":"4223622861662892","name":"你好兜","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4223622861662892","authorIdStr":"4223622861662892"},"themes":[],"title":"","htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/527084014653816","repostId":"1138825501","repostType":2,"repost":{"id":"1138825501","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1769653715,"share":"https://www.laohu8.com/m/news/1138825501?lang=zh_CN&edition=full","pubTime":"2026-01-29 10:28","market":"hk","language":"zh","title":"英矽智能涨近10%再创新高！开年仅一个月公司已达成三笔重磅合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1138825501","media":"老虎资讯综合","summary":"1月29日，$英矽智能$涨近10%，高见66.5港元，再创历史新高，开年仅一个月公司已达成三笔重磅合作。$浙商证券$发布研报称，AI制药核心价值在于大幅提升药物早研效率，以英矽智能Pharma.AI为例，其能够使候选药物从靶点发现到临床前候选药物确认时间从4.5年大幅缩短到12至18个月，早研阶段的投入产出比大幅提升。该行指出，国内多家AI制药平台服务能力全球领先，海外业务拓展持续高速已验证，关注英矽智能等。","content":"<html><head></head><body><p>1月29日，<a href=\"https://laohu8.com/S/03696\">英矽智能</a>涨近10%，高见66.5港元，再创历史新高，开年仅一个月公司已达成三笔重磅合作。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/af049c1303819858eb7acbf649ab03ac\" tg-width=\"560\" tg-height=\"240\"/></p><p>消息面上，开年仅一个月，英矽<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>已达成三笔重磅合作。1月5日，公司与施维雅达成8.88亿美元研发合作，聚焦创新抗肿瘤疗法；1月20日，与深圳衡泰<a href=\"https://laohu8.com/S/000504\">生物</a>就ISM8969项目达成合作，加速推进全球开发，双方各持50%权益，英矽智能主导IND申报及I期临床试验；1月27日，与齐鲁制药达成超9.31亿港元合作，关注代谢疾病领域新颖小分子药物设计与优化。</p><p style=\"text-align: justify;\"><a href=\"https://laohu8.com/S/601878\">浙商证券</a>发布研报称，AI制药核心价值在于大幅提升药物早研效率，以英矽智能Pharma.AI为例，其能够使候选药物从靶点发现到临床前候选药物确认时间从4.5年大幅缩短到12至18个月，早研阶段的投入产出比大幅提升。该行指出，国内多家AI制药平台服务能力全球领先，海外业务拓展持续高速已验证，关注英矽智能等。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>英矽智能涨近10%再创新高！开年仅一个月公司已达成三笔重磅合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n英矽智能涨近10%再创新高！开年仅一个月公司已达成三笔重磅合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2026-01-29 10:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>1月29日，<a href=\"https://laohu8.com/S/03696\">英矽智能</a>涨近10%，高见66.5港元，再创历史新高，开年仅一个月公司已达成三笔重磅合作。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/af049c1303819858eb7acbf649ab03ac\" tg-width=\"560\" tg-height=\"240\"/></p><p>消息面上，开年仅一个月，英矽<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>已达成三笔重磅合作。1月5日，公司与施维雅达成8.88亿美元研发合作，聚焦创新抗肿瘤疗法；1月20日，与深圳衡泰<a href=\"https://laohu8.com/S/000504\">生物</a>就ISM8969项目达成合作，加速推进全球开发，双方各持50%权益，英矽智能主导IND申报及I期临床试验；1月27日，与齐鲁制药达成超9.31亿港元合作，关注代谢疾病领域新颖小分子药物设计与优化。</p><p style=\"text-align: justify;\"><a href=\"https://laohu8.com/S/601878\">浙商证券</a>发布研报称，AI制药核心价值在于大幅提升药物早研效率，以英矽智能Pharma.AI为例，其能够使候选药物从靶点发现到临床前候选药物确认时间从4.5年大幅缩短到12至18个月，早研阶段的投入产出比大幅提升。该行指出，国内多家AI制药平台服务能力全球领先，海外业务拓展持续高速已验证，关注英矽智能等。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","relate_stocks":{"BK1141":"生命科学工具和服务","BK6092":"保健护理机构","03696":"英矽智能","01477":"欧康维视生物-B","BK6511":"医疗保健服务概念","5RE.SI":"智能"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138825501","content_text":"1月29日，英矽智能涨近10%，高见66.5港元，再创历史新高，开年仅一个月公司已达成三笔重磅合作。消息面上，开年仅一个月，英矽智能已达成三笔重磅合作。1月5日，公司与施维雅达成8.88亿美元研发合作，聚焦创新抗肿瘤疗法；1月20日，与深圳衡泰生物就ISM8969项目达成合作，加速推进全球开发，双方各持50%权益，英矽智能主导IND申报及I期临床试验；1月27日，与齐鲁制药达成超9.31亿港元合作，关注代谢疾病领域新颖小分子药物设计与优化。浙商证券发布研报称，AI制药核心价值在于大幅提升药物早研效率，以英矽智能Pharma.AI为例，其能够使候选药物从靶点发现到临床前候选药物确认时间从4.5年大幅缩短到12至18个月，早研阶段的投入产出比大幅提升。该行指出，国内多家AI制药平台服务能力全球领先，海外业务拓展持续高速已验证，关注英矽智能等。","news_type":1,"symbols_score_info":{"03696":1,"5RE.SI":1,"01477":0.47}},"isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
